Angiotensin receptor blockers shift the circadian rhythm of blood pressure by suppressing tubular sodium reabsorption

American Journal of Physiology - Renal Physiology

Volumn 301, Issue 5, 2011, Pages

  Fukuda, Michio ^a   Wakamatsu Yamanaka, Tamaki ^a   Mizuno, Masashi ^a   Miura, Toshiyuki ^a   Tomonari, Tatsuya ^a   Kato, Yoko ^a   Ichikawa, Tadashi ^a   Miyagi, Sota ^a   Shirasawa, Yuichi ^a   Ito, Akinori ^a   Yoshida, Atsuhiro ^a   Kimua, Genjiro ^a  

^a NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

Author keywords

Chronic kidney disease (CKD); Glomerulotubular balance; Nondipper; Olmesartan; Salt

Indexed keywords

OLMESARTAN; SODIUM;

ADOLESCENT; ADULT; AGED; ALBUMINURIA; ARTICLE; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE REGULATION; CHRONIC KIDNEY DISEASE; CIRCADIAN RHYTHM; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GLOMERULONEPHRITIS; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY TUBULE ABSORPTION; MALE; NATRIURESIS; NEPHROSCLEROSIS; PRIORITY JOURNAL; SODIUM EXCRETION; SODIUM INTAKE;

EID: 80055072956     PISSN: 1931857X     EISSN: 15221466     Source Type: Journal    
DOI: 10.1152/ajprenal.00167.2011     Document Type: Article

References (40)

1. Akita S, Sacks FM, Svetkey LP, Conlin PR, Kimura G; DASHSodium Trial Collaborative Research Group. Effects of the Dietary Approaches to Stop Hypertension (DASH) diet on the pressure-natriuresis relationship. Hypertension 42: 8-13, 2003.
2. Anderson S, Rennke HG, Garcia DL, Brenner BM. Short and long term effects of antihypertensive therapy in the diabetic rat. Kidney Int 36: 526-536, 1989.
3. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S; RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345: 861-869, 2001.
4. Castiglioni P, Parati G, Brambilla L, Brambilla V, Gualerzi M, Di Rienzo M, Coruzzi P. Detecting sodium-sensitivity in hypertensive patients: information from 24-hour ambulatory blood pressure monitoring. Hypertension 57: 180-185, 2011.
5. Coltamai L, Maillard M, Simon A, Vogt B, Burnier M. Comparative vascular and renal tubular effects of angiotensin II receptor blockers combined with a thiazide diuretic in humans. J Hypertens 28: 520-526, 2010.
6. DeClue JW, Guyton AC, Cowley AW Jr, Coleman TG, Norman RA Jr, McCaa RE. Subpressor angiotensin infusion, renal sodium handling, and salt-induced hypertension in the dog. Circ Res 43: 503-512, 1978.
7. de Jong PE, Anderson S, de Zeeuw D. Glomerular preload and afterload reduction as a tool to lower urinary protein leakage: will such treatments also help to improve renal function outcome? J Am Soc Nephrol 3: 1333-1341, 1993.
8. Fujii T, Uzu T, Nishimura M, Takeji M, Kuroda S, Nakamura S, Inenaga T, Kimura G. Circadian rhythm of natriuresis is disturbed in nondipper type of essential hypertension. Am J Kidney Dis 33: 29-35, 1999.
9. Fukuda M, Kimura G. Pathophysiology of antihypertensive therapy with diuretics. Hypertens Res 29: 645-653, 2006.
10. Fukuda M, Mizuno M, Yamanaka T, Motokawa M, Shirasawa Y, Nishio T, Miyagi S, Yoshida A, Kimura G. Patients with renal dysfunction require a longer duration until blood pressure dips during the night. Hypertension 52: 1155-1160, 2008.
11. Fukuda M, Munemura M, Usami T, Nakao N, Takeuchi O, Kamiya Y, Yoshida A, Kimura G. Nocturnal blood pressure is elevated with natriuresis and proteinuria as renal function deteriorates in nephropathy. Kidney Int 65: 621-625, 2004.
12. Fukuda M, Yamanaka T, Mizuno M, Motokawa M, Shirasawa Y, Miyagi S, Nishio T, Yoshida A, Kimura G. Angiotensin II type 1 receptor blocker, olmesartan, restores nocturnal blood pressure decline by enhancing daytime natriuresis. J Hypertens 26: 583-588, 2008.
13. García-Ortiz L, Gómez-Marcos MA, Martín-Moreiras J, González-Elena LJ, Recio-Rodriguez JI, Castaño-Sánchez Y, Grandes G, Martínez-Salgado C. Pulse pressure and nocturnal fall in blood pressure are predictors of vascular, cardiac and renal target organ damage in hypertensive patients (LOD-RISK study). Blood Press Monit 14: 145-151, 2009.
14. Guyton AC. Circulatory Physiology III. Arterial Pressure and Hypertension. Philadelphia, PA: Saunders, 1980.
15. Hall JE, Guyton AC, Smith MJ Jr, Coleman TG. Chronic blockade of angiotensin II formation during sodium deprivation. Am J Physiol Renal Fluid Electrolyte Physiol 237: F424-F432, 1979.
16. Higashi Y, Oshima T, Ozono R, Nakano Y, Matsuura H, Kambe M, Kajiyama G. Nocturnal decline in blood pressure is attenuated by NaCl loading in salt-sensitive patients with essential hypertension: noninvasive 24-hour ambulatory blood pressure monitoring. Hypertension 30: 163-167, 1997.
17. Ingelsson E, Björklund-Bodegård K, Lind L, Arnlöv J, Sundström J. Diurnal blood pressure pattern and risk of congestive heart failure. JAMA 295: 2859-2866, 2006.
18. Kimura G. Sodium, kidney, and circadian rhythm of blood pressure. Clin Exp Nephrol 5: 13-18, 2001.
19. Kimura G. Glomerular function reserve and sodium sensitivity. Clin Exp Nephrol 9: 102-113, 2005.
20. Kimura G. Kidney and circadian blood pressure rhythm. Hypertension 51: 827-828, 2008.
21. Kimura G, Brenner BM. The renal basis for salt sensitivity in hypertension. In: Hypertension: Pathophysiology, Diagnosis and Management (2nd ed.), edited by Laragh JH and Brenner BM. New York: Raven, 1995, p. 1569-1588.
22. Kimura G, Brenner BM. Implications of linear pressure-natriuresis relationship and importance of sodium sensitivity in hypertension. J Hypertens 15: 1055-1061, 1997.
23. Kimura G, Deguchi F, Kojima S, Ashida T, Yoshimi H, Abe H, Kawano Y, Yoshida K, Imanishi M, Kawamura M, Kuramochi M, Omae T. Antihypertensive drugs and sodium restriction. Analysis of their interaction based on pressure-natriuresis relationship. Am J Hypertens 1: 372-379, 1988.
24. Kimura G, Saito F, Kojima S, Yoshimi H, Abe H, Kawano Y, Yoshida K, Ashida T, Kawamura M, Kuramochi M, Ito K, Omae T. Renal function curve in patients with secondary forms of hypertension. Hypertension 10: 11-15, 1987.
25. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 329: 1456-1462, 1993.
26. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde R, Raz I; Collaborative Study Group. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345: 851-860, 2001.
27. Morimoto A, Uzu T, Fujii T, Nishimura M, Kuroda S, Nakamura S, Inenaga T, Kimura G. Sodium sensitivity and cardiovascular events in patients with essential hypertension. Lancet 350: 1734-1737, 1997.
28. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 39, Suppl 1: S1-S266, 2002.
29. O'Brien E, Sheridan J, O'Malley K. Dippers and non-dippers. Lancet 2: 397, 1988.
30. Oliverio MI, Best CF, Smithies O, Coffman TM. Regulation of sodium balance and blood pressure by the AT1A receptor for angiotensin II. Hypertension 35: 550-554, 2000.
31. Parving HH, Lehnert H, Bröchner-Mortensen J, Gomis R, Andersen S, Arner P; Irbesartan in Patients with Type 2 Diabetes, and Microalbuminuria Study Group. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 345: 870-878, 2001.
32. Polónia J, Diogo D, Caupers P, Damasceno A. Influence of two doses of irbesartan on non-dipper circadian blood pressure rhythm in salt-sensitive black hypertensives under high salt diet. J Cardiovasc Pharmacol 42: 98-104, 2003.
33. Portaluppi F, Smolensky MH. Perspectives on the chronotherapy of hypertension based on the results of the MAPEC study. Chronobiol Int 27: 1652-1667, 2010.
34. Saito F, Kimura G. Antihypertensive mechanism of diuretics based on pressure-natriuresis relationship. Hypertension 27: 914-918, 1996.
35. Tsioufis C, Andrikou I, Thomopoulos C, Petras D, Manolis A, Stefanadis C. Comparative prognostic role of nighttime blood pressure and nondipping profile on renal outcomes. Am J Nephrol 33: 277-288, 2011.
36. Uzu T, Ishikawa K, Fujii T, Nakamura S, Inenaga T, Kimura G. Sodium restriction shifts circadian rhythm of blood pressure from nondipper to dipper in essential hypertension. Circulation 96: 1859-1862, 1997.
37. Uzu T, Kazembe FS, Ishikawa K, Nakamura S, Inenaga T, Kimura G. High sodium sensitivity implicates nocturnal hypertension in essential hypertension. Hypertension 28: 139-142, 1996.
38. Uzu T, Kimura G. Diuretics shift circadian rhythm of blood pressure from nondipper to dipper in essential hypertension. Circulation 100: 1635-1638, 1999.
39. Uzu T, Nishimura M, Fujii T, Takeji M, Kuroda S, Nakamura S, Inenaga T, Kimura G. Changes in the circadian rhythm of blood pressure in primary aldosteronism in response to dietary sodium restriction and adrenalectomy. J Hypertens 16: 1745-1748, 1998.
40. Zatz R, Dunn BR, Meyer TW, Anderson S, Rennke HG, Brenner BM. Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension. J Clin Invest 77: 1925-1930, 1986.